Abstract
At our institution, protein electrophoretic (PEL) methods have been the mainstay for detecting and monitoring plasma cells disorders (PCD) since 1967. Although widely accepted by hematologist, these electrophoretic methods remain labor intensive and recent developments in treatments for PCDs are pushing electrophoresis to its analytical limits. Our group has recently published a series of articles describing clinically viable methods for M-protein detection and characterization based on mass spectrometry. Two variations of this technology have emerged: a MALDI-TOF MS method (MASS-FIX) and a LC-ESI-Triple TOF MS method (miRAMM) and are currently starting validation in our laboratory. The two methods share the same pre-analytical immunoglobulin purification but differ in their turnaround time, instrument cost, sensitivity and resolution.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
